People's Daily health client reporter Wang Aibing
"In order to meet the urgent need for clinical drugs in Chlorphazan, according to the relevant provisions of the "Temporary Import Work Plan for Drugs urgently needed for Clinical Use", the temporary import work plan for Chlorambucha is formulated." On March 29, the National Health Commission issued an announcement for public comment on the "Work Plan for the Temporary Import of ChlorpugalCan".
Previously, the People's Daily health client continued to post that the families of many children with rare diseases have released information for help. Their children developed rare epileptic encephalopathies such as infantile spasms, Dravet syndrome, LGS syndrome, Otahara syndrome, tuberous sclerosis, Fires syndrome, sequelae of encephalitis, and infantile epilepsy accompanied by wandering focal seizures (EIMFS) – these are rare diseases.
These children are required to take a medication called clopajan. According to the Catalogue of Psychotropic Substances (2013 Edition), chlorpal is a second-class psychotropic drug in mainland China and has not been approved for marketing and sale in China. The families of the children can only purchase clobats from abroad, so most of them are already at risk of discontinuation.
"Recently, because of the lack of medicines, we hope to help our children by sending out a real-name alliance to the whole society for help." In December 2021, the "SongSong Dad" of the child's family told the Health Times reporter that there are more than 1,600 children who need to take clobats and drugs, and most of them are already at risk of drug discontinuation.
"After the public consultation on the temporary import work plan of Chlorpal-Bachchan was issued, I sent this news to the family groups of our children, and parents were asking how to give advice, because there are many children whose parents are not very familiar with these procedures, and during this period of time, many children are facing the problem of drug discontinuation, so parents also hope to be able to quickly take this drug through legal channels." A family member of a child, Song Song Dad, told the People's Daily health client reporter.
Another parent who once helped us because his child could not buy Clobathan heard the news and sent 4 consecutive thanks, "Thank you to the state for giving the children a chance to take normal medicine." ”
It is understood that on March 11, Yichang Renfu Pharmaceutical submitted a 3-class imitation listing application for clobazhan tablets and was undertaken by the Drug Review Center of the State Food and Drug Administration. According to the above plan, the medical institutions to be led in the import and use of chlorobazan include 50 medical institutions such as Peking Union Medical College Hospital, Peking University First Hospital, Beijing Children's Hospital, and Huashan Hospital affiliated to Fudan University.
